LIVE

PCRX

Pacira BioSciences, Inc.

PCRX

NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $984.6M

$25.39

▲ +1.44%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$18.80 - $27.64

P/E

211.23

Fwd P/E

7.45

Beta

0.29

Div Yield

0.00%

Avg Vol

528.0K

Shares Out

43.0M

Mkt Cap

$984.6M

Price action

Price chart

Up 7.8% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Proprietary multivesicular liposome (MVL) drug delivery technology enabling extended-release formulations
  • Diversified non-opioid product portfolio addressing multiple pain management indications
  • Strong clinical evidence and healthcare provider adoption in surgical and orthopedic markets
  • Regulatory exclusivity and patent protection for core products
▼

Bear Case

1 risk

  • Low volatility (beta 0.3).

Growth

Stable outlook

Rising adoption of opioid-sparing pain management protocols in hospitals and surgical centers

Value

Undervalued - trading well below Large Cap Pharma peers

Momentum

Strong

+10.3% over 3m

Quality

Excellent

Excellent business quality

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Aug 4, 2026

“
Q2 26 RECAP

APR 30, 2026

Reported EPS of $0.60 vs $0.61 consensus (-1.6% surprise). Revenue of $177.4M vs $171.8M expected (+3.3%).

EPS miss
Rev beat +3.3%

EPS surprise · last 4Q

0 of 1 beats

Q2 26

-1.6%

Next: Aug 4, 2026

Revenue trend · last 8Q

—

—

+3%

+1%

+2%

+6%

+5%

+5%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$178.0M

$168.6M

$187.3M

$168.9M

$181.1M

$179.5M

$196.9M

$177.4M

Margins · last 8Q

Gross

—

Operating

—

Profit

1.6%

View full earnings history →

Wall Street consensus

3 analysts · 33% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

1

33%

Hold

2

67%

Sell

0%

Median Price Target

$32.00

▲ +26.0% vs $25.39

Low $32.00
Median $32.00
High $32.00

Latest: Needham · $32.00 · May 1, 2026

1 analyst covering

View full analyst page →

vs Industry

How PCRX stacks vs Drug Manufacturers - Specialty & Generic

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.